iSpecimen Inc (ISPC) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financials are weak, with significant revenue declines and poor profitability metrics. Technical indicators suggest bearish momentum, and there are no positive trading signals or catalysts to support a buy decision at this time.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 38.188, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 0.234), with resistance levels at R1: 0.302 and R2: 0.323. Overall, the trend indicates downward momentum.
NULL identified. There is no recent news, and no significant trading activity from hedge funds, insiders, or Congress.
The company's financial performance is extremely weak, with a 96% YoY revenue drop in Q3 2025, a gross margin decline of -321.27%, and a negative EPS trend. Technical indicators also suggest bearish momentum.
In Q3 2025, revenue dropped by 96% YoY to $106,592, net income improved slightly but remains negative at -$2,780,648 (up 93.12% YoY), EPS fell to -0.48 (down 77.14% YoY), and gross margin dropped to -92.05% (down 321.27% YoY). Overall, the financials are highly unfavorable.
No analyst ratings or price target changes available for ISPC.
